Détail de l'auteur
Auteur Catherine Leggett
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche Interroger des sources externes
Antidepressant Use in Late Gestation and Breastfeeding Rates at Discharge from Hospital / Catherine Leggett in Journal of Human Lactation, Vol. 33, n°4 (Novembre 2017)
Titre : Antidepressant Use in Late Gestation and Breastfeeding Rates at Discharge from Hospital Type de document : texte imprimé Auteurs : Catherine Leggett, Auteur ; Lynn Costi, Auteur ; Janna L. Morrison, Auteur Année de publication : 2017 Article en page(s) : pp. 701–709 Langues : Anglais (eng) Catégories : Antidépresseur
Soutien aux mères
Résumé : This study aimed to evaluate the association between antidepressant use in late gestation and maternal psychiatric illness on breastfeeding rates at discharge from hospital.
While antidepressant use is associated with a reduction in breastfeeding rates, this association appears to be strongly influenced by factors such as underlying maternal psychiatric illness. Overall, these results highlight that these women may benefit from additional education and support to improve breastfeeding rates.
in Journal of Human Lactation > Vol. 33, n°4 (Novembre 2017) . - pp. 701–709[article]Estimation of Atenolol Transfer Into Milk and Infant Exposure During Its Use in Lactating Women / Ei Mon Phyo Lwin in Journal of Human Lactation, Vol. 34, n°3 (Août 2018)
Titre : Estimation of Atenolol Transfer Into Milk and Infant Exposure During Its Use in Lactating Women Type de document : texte imprimé Auteurs : Ei Mon Phyo Lwin, Auteur ; Cobus Gerber, Auteur ; Catherine Leggett, Auteur Année de publication : 2018 Article en page(s) : pp. 592-599 Langues : Anglais (eng) Catégories : Composition du lait
Consultant.e en lactation
Thérapeutique médicamenteuse de la mère
Résumé : "Abstract
Atenolol lactation information is limited, and controversy exists over the safety of its use during breastfeeding. In this study, important parameters including milk-to-plasma ratio, ratio of infant plasma to maternal plasma, infant daily dosage, and relative infant dose were investigated. The findings from this study add information to existing data about atenolol transfer in human milk. This may help guide health professionals in decision making regarding the safety of beta blockers used by mothers during breastfeeding.
The aims of the study were to quantify concentrations of atenolol in human plasma and milk, to evaluate atenolol pharmacokinetics in lactating women, and to investigate subsequent infant exposure to atenolol via mother’s milk.
In this prospective, longitudinal observational study, participants were lactating mothers (N = 3), 1 to 4 months postpartum, who had been taking atenolol for therapeutic reasons, and one 4-month-old breastfed infant. Eight milk samples were collected over 24 hr at different time points, together with a single blood sample from each lactating mother and the infant, and quantified using a new sensitive liquid chromatography mass spectrometry method developed for this study.
Peak milk concentrations of atenolol were observed in the women at 4 hr (Tmax) after oral administration. The dose-normalized maximum concentrations (Cmax) of all patients were similar. The mean milk-to-plasma ratio of the patients who were taking 25 to 100 mg of atenolol was 8.57%. In the mother–infant pair study, the ratio (%) of infant plasma drug concentration to maternal plasma drug concentration observed (18.87%) was similar to the relative infant dose estimated (18.20%). The relative infant dose values (13.96%-18.20%) for all patients were within 10% to 25% of maternal dosage.
Atenolol use during breastfeeding should be undertaken with some precaution. If clinically indicated, an alternate beta blocker may be preferred."
[Résumé de l'auteur]
in Journal of Human Lactation > Vol. 34, n°3 (Août 2018) . - pp. 592-599[article]